EVEROLIMUS
IMMUNOSUPPRESSANTS - MTOR INHIBITORS · PREVENTION OF KIDNEY TRANSPLANT REJECTION ·+1
AUROBINDO PHARM
Drug class
Immunosuppressants - mTOR Inhibitors
Immunosuppressants in the mTOR inhibitor class are antiproliferative agents, primarily represented by sirolimus and everolimus, that target the mammalian target of rapamycin kinase pathway. Read more about Immunosuppressants - mTOR Inhibitors
37 drugs in this class 29 manufacturers
Drugs in Immunosuppressants - mTOR Inhibitors
Filter & compare in the drug finder →
Opens the drug finder with Immunosuppressants - mTOR Inhibitors preselected. Add indication or manufacturer filters there.
Immunosuppressants in the mTOR inhibitor class are antiproliferative agents, primarily represented by sirolimus and everolimus, that target the mammalian target of rapamycin kinase pathway.
Mechanistically, these agents bind to the intracellular immunophilin FKBP12 to inhibit mTOR complex 1 signaling, which blocks interleukin-2-driven downstream signal transduction and halts lymphocyte progression from the G1 to S phase of the cell cycle.
Their primary therapeutic role is to suppress T-cell proliferation and immune activation to prevent organ allograft rejection following solid organ transplantation, particularly in kidney and liver recipients.
They are also utilized to manage specific non-malignant proliferative conditions, such as lymphangioleiomyomatosis, and serve as non-nephrotoxic alternatives or adjuncts to calcineurin inhibitors.
-
nih.gov
Immunosuppressants in the mTOR inhibitor class are antiproliferative agents, primarily represented by sirolimus and everolimus, that target the mammalian target of rapamycin kinase pathway Their primary therapeutic role is to suppress T-cell proliferation and immune activation to prevent organ allograft rejection following solid organ transplantation, particularly in kidney and liver recipients
-
nih.gov
Immunosuppressants in the mTOR inhibitor class are antiproliferative agents, primarily represented by sirolimus and everolimus, that target the mammalian target of rapamycin kinase pathway
-
nih.gov
Mechanistically, these agents bind to the intracellular immunophilin FKBP12 to inhibit mTOR complex 1 signaling, which blocks interleukin-2-driven downstream signal transduction and halts lymphocyte progression from the G1 to S phase of the cell cycle Their primary therapeutic role is to suppress T-cell proliferation and immune activation to prevent organ allograft rejection following solid organ transplantation, particularly in kidney and liver recipients
-
nih.gov
Mechanistically, these agents bind to the intracellular immunophilin FKBP12 to inhibit mTOR complex 1 signaling, which blocks interleukin-2-driven downstream signal transduction and halts lymphocyte progression from the G1 to S phase of the cell cycle
-
nih.gov
Mechanistically, these agents bind to the intracellular immunophilin FKBP12 to inhibit mTOR complex 1 signaling, which blocks interleukin-2-driven downstream signal transduction and halts lymphocyte progression from the G1 to S phase of the cell cycle
-
nih.gov
Their primary therapeutic role is to suppress T-cell proliferation and immune activation to prevent organ allograft rejection following solid organ transplantation, particularly in kidney and liver recipients
-
nih.gov
They are also utilized to manage specific non-malignant proliferative conditions, such as lymphangioleiomyomatosis, and serve as non-nephrotoxic alternatives or adjuncts to calcineurin inhibitors
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.